Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California. more
Time Frame | ANTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.7% | -0.4% | -1.9% |
1-Month Return | 0.72% | -4.57% | -0.37% |
3-Month Return | 34.62% | -10.14% | 4.19% |
6-Month Return | -32.37% | -5.67% | 9.34% |
1-Year Return | -93.28% | 2.53% | 25.19% |
3-Year Return | -90.91% | -0.39% | 26.48% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | 77.00K | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | - | - | (77.00K) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-7700000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 5.18M | 7.28M | 21.57M | 42.26M | 69.64M | [{"date":"2019-12-31","value":7.44,"profit":true},{"date":"2020-12-31","value":10.46,"profit":true},{"date":"2021-12-31","value":30.98,"profit":true},{"date":"2022-12-31","value":60.69,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (5.18M) | (7.28M) | (21.57M) | (42.26M) | (69.64M) | [{"date":"2019-12-31","value":-517800000,"profit":false},{"date":"2020-12-31","value":-728400000,"profit":false},{"date":"2021-12-31","value":-2157400000,"profit":false},{"date":"2022-12-31","value":-4226200000,"profit":false},{"date":"2023-12-31","value":-6963500000,"profit":false}] |
Total Non-Operating Income/Expense | - | (6.32M) | 100.00K | 2.66M | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-237.71,"profit":false},{"date":"2021-12-31","value":3.76,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (5.63M) | (13.60M) | (21.54M) | (40.96M) | (64.73M) | [{"date":"2019-12-31","value":-563500000,"profit":false},{"date":"2020-12-31","value":-1360300000,"profit":false},{"date":"2021-12-31","value":-2154300000,"profit":false},{"date":"2022-12-31","value":-4095600000,"profit":false},{"date":"2023-12-31","value":-6473200000,"profit":false}] |
Income Taxes | (31.07K) | (3.00K) | (69.00K) | 514.00K | (69.64K) | [{"date":"2019-12-31","value":-6.04,"profit":false},{"date":"2020-12-31","value":-0.58,"profit":false},{"date":"2021-12-31","value":-13.42,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-13.55,"profit":false}] |
Income After Taxes | - | (13.60M) | (21.47M) | (41.47M) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1360000000,"profit":false},{"date":"2021-12-31","value":-2147400000,"profit":false},{"date":"2022-12-31","value":-4147000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | - | (13.60M) | (21.54M) | (40.96M) | (59.68M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1360300000,"profit":false},{"date":"2021-12-31","value":-2154300000,"profit":false},{"date":"2022-12-31","value":-4095600000,"profit":false},{"date":"2023-12-31","value":-5967600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (5.63M) | (13.60M) | (21.47M) | (41.47M) | (64.73M) | [{"date":"2019-12-31","value":-563500000,"profit":false},{"date":"2020-12-31","value":-1360000000,"profit":false},{"date":"2021-12-31","value":-2147400000,"profit":false},{"date":"2022-12-31","value":-4147000000,"profit":false},{"date":"2023-12-31","value":-6473200000,"profit":false}] |
EPS (Diluted) | - | - | - | (4.71) | (2.82) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-471,"profit":false},{"date":"2023-12-31","value":-282,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ANTX | |
---|---|
Cash Ratio | 9.33 |
Current Ratio | 9.75 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ANTX | |
---|---|
ROA (LTM) | -42.89% |
ROE (LTM) | -69.48% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ANTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ANTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.48 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
AN2 Therapeutics Inc (ANTX) share price today is $1.365
Yes, Indians can buy shares of AN2 Therapeutics Inc (ANTX) on Vested. To buy AN2 Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of AN2 Therapeutics Inc (ANTX) via the Vested app. You can start investing in AN2 Therapeutics Inc (ANTX) with a minimum investment of $1.
You can invest in shares of AN2 Therapeutics Inc (ANTX) via Vested in three simple steps:
The 52-week high price of AN2 Therapeutics Inc (ANTX) is $22.22. The 52-week low price of AN2 Therapeutics Inc (ANTX) is $0.87.
The price-to-earnings (P/E) ratio of AN2 Therapeutics Inc (ANTX) is
The price-to-book (P/B) ratio of AN2 Therapeutics Inc (ANTX) is 0.48
The dividend yield of AN2 Therapeutics Inc (ANTX) is 0.00%
The market capitalization of AN2 Therapeutics Inc (ANTX) is $41.83M
The stock symbol (or ticker) of AN2 Therapeutics Inc is ANTX